Macrophage Notch Ligand Delta-Like 4 Promotes Vein Graft Lesion Development: Implications for the Treatment of Vein Graft Failure

Jun Ichiro Koga, Toshiaki Nakano, James E. Dahlman, Jose Luiz Figueiredo, Hengmin Zhang, Julius Decano, Omar F. Khan, Tomiharu Niida, Hiroshi Iwata, Jon C. Aster, Hideo Yagita, Daniel G. Anderson, C. Keith Ozaki, Masanori Aikawa

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective-Despite its large clinical impact, the underlying mechanisms for vein graft failure remain obscure and no effective therapeutic solutions are available. We tested the hypothesis that Notch signaling promotes vein graft disease. Approach and Results-We used 2 biotherapeutics for Delta-like ligand 4 (Dll4), a Notch ligand: (1) blocking antibody and (2) macrophage-or endothelial cell (EC)-targeted small-interfering RNA. Dll4 antibody administration for 28 days inhibited vein graft lesion development in low-density lipoprotein (LDL) receptor-deficient (Ldlr-/-) mice, and suppressed macrophage accumulation and macrophage expression of proinflammatory M1 genes. Dll4 antibody treatment for 7 days after grafting also reduced macrophage burden at day 28. Dll4 silencing via macrophage-targeted lipid nanoparticles reduced lesion development and macrophage accumulation, whereas EC-targeted Dll4 small-interfering RNA produced no effects. Gain-of-function and loss-of-function studies suggested in vitro that Dll4 induces proinflammatory molecules in macrophages. Macrophage Dll4 also stimulated smooth muscle cell proliferation and migration and suppressed their differentiation. Conclusions-These results suggest that macrophage Dll4 promotes lesion development in vein grafts via macrophage activation and crosstalk between macrophages and smooth muscle cells, supporting the Dll4-Notch axis as a novel therapeutic target.

Original languageEnglish
Pages (from-to)2343-2353
Number of pages11
JournalArteriosclerosis, thrombosis, and vascular biology
Volume35
Issue number11
DOIs
Publication statusPublished - Nov 1 2015
Externally publishedYes

Fingerprint

Veins
Macrophages
Transplants
Small Interfering RNA
Smooth Muscle Myocytes
Endothelial Cells
delta protein
Blocking Antibodies
Macrophage Activation
Antibodies
LDL Receptors
Nanoparticles
Cell Movement
Cell Proliferation
Ligands
Lipids
Therapeutics
Genes

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Macrophage Notch Ligand Delta-Like 4 Promotes Vein Graft Lesion Development : Implications for the Treatment of Vein Graft Failure. / Koga, Jun Ichiro; Nakano, Toshiaki; Dahlman, James E.; Figueiredo, Jose Luiz; Zhang, Hengmin; Decano, Julius; Khan, Omar F.; Niida, Tomiharu; Iwata, Hiroshi; Aster, Jon C.; Yagita, Hideo; Anderson, Daniel G.; Keith Ozaki, C.; Aikawa, Masanori.

In: Arteriosclerosis, thrombosis, and vascular biology, Vol. 35, No. 11, 01.11.2015, p. 2343-2353.

Research output: Contribution to journalArticle

Koga, JI, Nakano, T, Dahlman, JE, Figueiredo, JL, Zhang, H, Decano, J, Khan, OF, Niida, T, Iwata, H, Aster, JC, Yagita, H, Anderson, DG, Keith Ozaki, C & Aikawa, M 2015, 'Macrophage Notch Ligand Delta-Like 4 Promotes Vein Graft Lesion Development: Implications for the Treatment of Vein Graft Failure', Arteriosclerosis, thrombosis, and vascular biology, vol. 35, no. 11, pp. 2343-2353. https://doi.org/10.1161/ATVBAHA.115.305516
Koga, Jun Ichiro ; Nakano, Toshiaki ; Dahlman, James E. ; Figueiredo, Jose Luiz ; Zhang, Hengmin ; Decano, Julius ; Khan, Omar F. ; Niida, Tomiharu ; Iwata, Hiroshi ; Aster, Jon C. ; Yagita, Hideo ; Anderson, Daniel G. ; Keith Ozaki, C. ; Aikawa, Masanori. / Macrophage Notch Ligand Delta-Like 4 Promotes Vein Graft Lesion Development : Implications for the Treatment of Vein Graft Failure. In: Arteriosclerosis, thrombosis, and vascular biology. 2015 ; Vol. 35, No. 11. pp. 2343-2353.
@article{fc974c4513604f75ba41e34b6caacb1b,
title = "Macrophage Notch Ligand Delta-Like 4 Promotes Vein Graft Lesion Development: Implications for the Treatment of Vein Graft Failure",
abstract = "Objective-Despite its large clinical impact, the underlying mechanisms for vein graft failure remain obscure and no effective therapeutic solutions are available. We tested the hypothesis that Notch signaling promotes vein graft disease. Approach and Results-We used 2 biotherapeutics for Delta-like ligand 4 (Dll4), a Notch ligand: (1) blocking antibody and (2) macrophage-or endothelial cell (EC)-targeted small-interfering RNA. Dll4 antibody administration for 28 days inhibited vein graft lesion development in low-density lipoprotein (LDL) receptor-deficient (Ldlr-/-) mice, and suppressed macrophage accumulation and macrophage expression of proinflammatory M1 genes. Dll4 antibody treatment for 7 days after grafting also reduced macrophage burden at day 28. Dll4 silencing via macrophage-targeted lipid nanoparticles reduced lesion development and macrophage accumulation, whereas EC-targeted Dll4 small-interfering RNA produced no effects. Gain-of-function and loss-of-function studies suggested in vitro that Dll4 induces proinflammatory molecules in macrophages. Macrophage Dll4 also stimulated smooth muscle cell proliferation and migration and suppressed their differentiation. Conclusions-These results suggest that macrophage Dll4 promotes lesion development in vein grafts via macrophage activation and crosstalk between macrophages and smooth muscle cells, supporting the Dll4-Notch axis as a novel therapeutic target.",
author = "Koga, {Jun Ichiro} and Toshiaki Nakano and Dahlman, {James E.} and Figueiredo, {Jose Luiz} and Hengmin Zhang and Julius Decano and Khan, {Omar F.} and Tomiharu Niida and Hiroshi Iwata and Aster, {Jon C.} and Hideo Yagita and Anderson, {Daniel G.} and {Keith Ozaki}, C. and Masanori Aikawa",
year = "2015",
month = "11",
day = "1",
doi = "10.1161/ATVBAHA.115.305516",
language = "English",
volume = "35",
pages = "2343--2353",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Macrophage Notch Ligand Delta-Like 4 Promotes Vein Graft Lesion Development

T2 - Implications for the Treatment of Vein Graft Failure

AU - Koga, Jun Ichiro

AU - Nakano, Toshiaki

AU - Dahlman, James E.

AU - Figueiredo, Jose Luiz

AU - Zhang, Hengmin

AU - Decano, Julius

AU - Khan, Omar F.

AU - Niida, Tomiharu

AU - Iwata, Hiroshi

AU - Aster, Jon C.

AU - Yagita, Hideo

AU - Anderson, Daniel G.

AU - Keith Ozaki, C.

AU - Aikawa, Masanori

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Objective-Despite its large clinical impact, the underlying mechanisms for vein graft failure remain obscure and no effective therapeutic solutions are available. We tested the hypothesis that Notch signaling promotes vein graft disease. Approach and Results-We used 2 biotherapeutics for Delta-like ligand 4 (Dll4), a Notch ligand: (1) blocking antibody and (2) macrophage-or endothelial cell (EC)-targeted small-interfering RNA. Dll4 antibody administration for 28 days inhibited vein graft lesion development in low-density lipoprotein (LDL) receptor-deficient (Ldlr-/-) mice, and suppressed macrophage accumulation and macrophage expression of proinflammatory M1 genes. Dll4 antibody treatment for 7 days after grafting also reduced macrophage burden at day 28. Dll4 silencing via macrophage-targeted lipid nanoparticles reduced lesion development and macrophage accumulation, whereas EC-targeted Dll4 small-interfering RNA produced no effects. Gain-of-function and loss-of-function studies suggested in vitro that Dll4 induces proinflammatory molecules in macrophages. Macrophage Dll4 also stimulated smooth muscle cell proliferation and migration and suppressed their differentiation. Conclusions-These results suggest that macrophage Dll4 promotes lesion development in vein grafts via macrophage activation and crosstalk between macrophages and smooth muscle cells, supporting the Dll4-Notch axis as a novel therapeutic target.

AB - Objective-Despite its large clinical impact, the underlying mechanisms for vein graft failure remain obscure and no effective therapeutic solutions are available. We tested the hypothesis that Notch signaling promotes vein graft disease. Approach and Results-We used 2 biotherapeutics for Delta-like ligand 4 (Dll4), a Notch ligand: (1) blocking antibody and (2) macrophage-or endothelial cell (EC)-targeted small-interfering RNA. Dll4 antibody administration for 28 days inhibited vein graft lesion development in low-density lipoprotein (LDL) receptor-deficient (Ldlr-/-) mice, and suppressed macrophage accumulation and macrophage expression of proinflammatory M1 genes. Dll4 antibody treatment for 7 days after grafting also reduced macrophage burden at day 28. Dll4 silencing via macrophage-targeted lipid nanoparticles reduced lesion development and macrophage accumulation, whereas EC-targeted Dll4 small-interfering RNA produced no effects. Gain-of-function and loss-of-function studies suggested in vitro that Dll4 induces proinflammatory molecules in macrophages. Macrophage Dll4 also stimulated smooth muscle cell proliferation and migration and suppressed their differentiation. Conclusions-These results suggest that macrophage Dll4 promotes lesion development in vein grafts via macrophage activation and crosstalk between macrophages and smooth muscle cells, supporting the Dll4-Notch axis as a novel therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=84945477836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945477836&partnerID=8YFLogxK

U2 - 10.1161/ATVBAHA.115.305516

DO - 10.1161/ATVBAHA.115.305516

M3 - Article

C2 - 26404485

AN - SCOPUS:84945477836

VL - 35

SP - 2343

EP - 2353

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 11

ER -